title: Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
abstract: BACKGROUND
  The aim of this phase I study was to define the maximum tolerated dose (MTD) of thiotepa (TT), administered with busulfan (BU) 480 mg/m(2) and etoposide 2,400 mg/m(2), followed by autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (APBSCT) support in children with solid tumors either disseminated at diagnosis or after relapse.
  
  
  METHODS
  Nineteen patients, between 2 and 16 years of age, received a high-dose chemotherapy regimen including escalating doses of TT starting from 150 mg/m(2). Subsequent dose escalation was determined by a modified Fibonacci scheme. Whenever one patient at one dosage level showed a grade III or grade IV reversible toxicity, additional patients were admitted (one by one) up to a maximum number of 6. Upon observing grade III or IV reversible toxicity in two or more systems, in 3 of the 6 patients, no further escalation was performed, and the corresponding dosage was taken as the MTD. WHO criteria were adopted to assess grade of toxicity.
  
  
  RESULTS
  All patients had hematological recovery; and neutrophils and platelet engraftment were observed after median times of 12 and 29 days from stem cell infusion, respectively. The MTD of TT was determined to be 750 mg/ m(2). At this level, 3 of 6 patients experienced grade III mucositis and/or grade III gastrointestinal toxicity. No patient died of treatment-related toxicity.
  
  
  CONCLUSIONS
  A dose of 750 mg/m(2) TT is the MTD when it is associated with BU 480 mg/m(2) and etoposide 2, 400 mg/m(2). This ablative regimen represents a feasible and tolerable combination for high-dose chemotherapy followed by hematopoietic stem cell rescue (HSCR). Phase II studies in children with poor-prognosis solid tumors are required to evaluate the effectiveness of this treatment.
authors.affiliation: Clinica Pediatrica, Università di Bologna, Bologna, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Pession
authors.forename: A
authors.initials: A
authors.lastname: Prete
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
authors.forename: S
authors.initials: S
authors.lastname: Bella
authors.forename: F
authors.initials: F
authors.lastname: Melchionda
authors.forename: A
authors.initials: A
authors.lastname: Garaventa
authors.forename: R
authors.initials: R
authors.lastname: Burnelli
authors.forename: G
authors.initials: G
authors.lastname: Paolucci
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002066:Busulfan / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D009447:Neuroblastoma / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D012208:Rhabdomyosarcoma / Q000473:pathology / Q000628:therapy*; D012512:Sarcoma, Ewing / Q000473:pathology / Q000628:therapy*; D013852:Thiotepa / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D005047:Etoposide; D013852:Thiotepa; D002066:Busulfan